The ARREST Trial (2023) was a multicenter, open-label, randomized controlled study that assessed whether expedited transfer of resuscitated out-of-hospital cardiac arrest (OHCA) patients without ST-elevation to a cardiac arrest center (CAC) improved outcomes compared with transfer to the nearest emergency … Read More
Cardiovascular Disease
AQUATIC Trial: Aspirin + OAC in CAD
The AQUATIC trial (2025) was a double-blind, randomized, placebo-controlled study that evaluated the effect of adding aspirin to long-term oral anticoagulation in patients with chronic coronary syndrome (CCS) at high atherothrombotic risk. A total of 872 patients on oral anticoagulation … Read More
Essence-TIMI 73b: Olezarsen Significantly Reduces Triglycerides in High-Risk Patients
Hypertriglyceridemia remains a major challenge in cardiovascular care, linked with increased risk of atherosclerotic cardiovascular disease (ASCVD) and pancreatitis. While lifestyle modifications and current lipid-lowering therapies can help, many patients still require additional treatment options. The Essence-TIMI 73b trial, published … Read More
VICTORION-Mono Trial: Inclisiran for Primary Prevention
Inclisiran in the Spotlight: The VICTORION-Mono Trial Shakes Up Primary Prevention Breaking New Ground in LDL-C Management A landmark study, VICTORION‑Mono (V‑Mono), reveals that inclisiran—a twice-yearly, small interfering RNA (siRNA) designed to inhibit PCSK9—is significantly more effective than both placebo … Read More
Left Ventricular Hypertrophy ECG Criteria Infographic
LVH Criteria on ECG 🧠 Remember: ECG has low sensitivity but high specificity for LVH. ✅ Sokolow-Lyon Criteria ✅ Cornell Criteria ✅ Romhilt-Estes Point Score System ⚡ LVH-Associated ST-T Changes (Strain Pattern)
Right Heart Catheterization: A Quick Interpretation Guide
Right Heart Catheterization (RHC) is a critical tool for diagnosing and managing various cardiovascular and pulmonary conditions. This invasive hemodynamic assessment provides real-time insight into the function and pressures of the right heart, pulmonary arteries, and left heart indirectly via … Read More
Altshock-2 Trial: IABP in Cardiogenic Shock
Altshock-2 Trial: Evaluating Early IABP Support in Cardiogenic Shock The Altshock-2 trial is a multicenter, prospective study designed to evaluate the efficacy of early intra-aortic balloon pump (IABP) support in patients with heart failure-related cardiogenic shock (HF-CS). This trial aimed … Read More
DapaTAVI Trial: Dapagliflozin in TAVR
The year 2025 brought several influential cardiovascular studies to light, and among the most promising was the DapaTAVI trial. This randomized, open-label trial explored the impact of dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, in a population often seen as high-risk … Read More
WARRIOR Trial: Women’s Ischemia Trial, Treating Non-Obstructive Coronary Artery Disease
In the ever-evolving landscape of cardiovascular research, the WARRIOR trial—short for Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD—has emerged as a pivotal investigation into how best to treat women with ischemia and no obstructive coronary artery disease (INOCA). … Read More
API-CAT Trial: Evaluating Low-Dose Apixaban for Cancer-Associated Thrombosis
API-CAT Trial: Evaluating Low-Dose Apixaban for Cancer-Associated Thrombosis Introduction The API-CAT trial is a groundbreaking study designed to evaluate whether a reduced dose of apixaban (2.5 mg twice daily) is as effective as the standard full-dose regimen (5 mg twice … Read More